The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Could CSF1R expression be used as a prognostic biomarker in gastric cancer?
Kyosuke Seguchi, MD, Kameda Medical Center, Kamogawa, Japan, discusses the further validation that needs to occur before CSF1R expression can be used as a prognostic biomarker in gastric cancer. The association between CSF1R expression and prognostic will need to be confirmed in a new independent cohort and the optimal cutoff of CSF1R expression will need to be evaluated. In addition, validation at the protein, single-cell and transcriptomic level will be needed in order to distinguish between CSF1R expression in tumor-associated macrophages and other cells including tumor-adjacent stromal components. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
